In a monumental development for global women’s health and endocrinology, the medical community has officially retired the term "Polycystic Ovary Syndrome" (PCOS). As of May 12, 2026, following a rigorous 14-year international consensus process, the condition has been formally renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).
This transition, announced in the pages of The Lancet, is far more than a semantic adjustment. It represents a fundamental recalibration of how medicine views a condition that affects millions, including a significant cohort—roughly 17% of patients with hypermobile Ehlers-Danlos Syndrome (hEDS) and 14.7% of those with Hypermobility Spectrum Disorders (HSD). For these patients, who have long navigated the intersections of chronic pain, hormonal dysfunction, and systemic hypermobility, this name change serves as a long-overdue validation of the condition’s true, multisystem nature.
The Evolution of a Name: A Historical Perspective
The history of the condition now known as PMOS is a testament to the evolving understanding of endocrine health. Since its initial descriptions in early 20th-century medical literature, the syndrome has carried an identity crisis. It has been referred to by various monikers, including:
- Polycystic ovary disorder
- Functional ovary androgenism
- Hyperandrogenic chronic anovulation
- Ovarian dysmetabolic syndrome
- Sclerotic polycystic ovary syndrome
Each of these labels reflected the prevailing, albeit limited, scientific focus of its time. However, as the 21st century progressed, the medical community became increasingly aware that focusing on the "polycystic" aspect of the ovaries was akin to describing a systemic house fire by only pointing at the smoke in the kitchen.
Why the Change Was Necessary
The term "Polycystic Ovary Syndrome" became a diagnostic and clinical liability. By centering the name on the ovaries—and specifically on the presence of cysts—the medical establishment inadvertently narrowed the scope of research and patient care.
1. The "Cyst" Misnomer
The most significant issue with the former name was its inaccuracy. Many patients diagnosed with the syndrome do not exhibit polycystic ovarian morphology on ultrasound. This led to "diagnostic limbo," where patients experiencing severe hormonal and metabolic symptoms were denied a diagnosis because they lacked the specific ovarian presentation, while others were over-treated based on imaging alone.
2. Siloing Care
By labeling the condition as a "reproductive" issue, healthcare systems relegated it to the domain of gynecology. This effectively cut off access to metabolic specialists, endocrinologists, and cardiologists who are essential for managing the systemic complications of the disease.
3. The New Definition: Breaking Down PMOS
The rebranding to Polyendocrine Metabolic Ovarian Syndrome was deliberate and descriptive:
- Polyendocrine: Acknowledges that the condition is driven by a complex interplay of insulin, androgens, and neuroendocrine hormones.
- Metabolic: Highlights the inherent risks associated with the condition, including insulin resistance, obesity, and significantly elevated risks for Type 2 diabetes and cardiovascular disease.
- Ovarian: Retained because, while cysts are not the primary driver, ovulatory dysfunction remains a clinical hallmark of the syndrome.
Chronology of the Reclassification
The shift to PMOS did not happen overnight. It was the result of a decade and a half of global collaboration.
- 2012: Initial international discussions begin regarding the inadequacy of the PCOS label.
- 2018–2023: Global working groups, including the World Health Organization and leading endocrine societies, initiate a formal review of diagnostic nomenclature.
- 2024: A draft proposal for "Polyendocrine Metabolic Ovarian Syndrome" gains traction, focusing on metabolic phenotypes.
- May 12, 2026: The Lancet publishes the formal consensus, officially codifying the name as PMOS.
- 2026–2029: A three-year transition period begins, involving the integration of the name into international disease classification systems (ICD).
- 2028: The International Guideline—utilized in 195 countries—is scheduled for a full update, cementing PMOS as the global standard.
Supporting Data: The Funding Gap
Perhaps the most compelling argument for the name change is the disparity in medical funding. Between 2016 and 2022, research funding for the condition (then PCOS) averaged approximately $32 million. In contrast, conditions with similar or even lower patient mortality rates—such as systemic lupus erythematosus ($420 million) and rheumatoid arthritis ($262 million)—received significantly higher allocations.
By rebranding as a metabolic and endocrine disorder, advocates and researchers expect the condition to qualify for grants from National Institutes of Health (NIH) divisions focused on diabetes, cardiovascular health, and internal medicine. This is a crucial step toward "deprioritizing" the reproductive-only lens and "prioritizing" the whole-body health of the patient.
The Intersection with hEDS and HSD
For the hEDS and HSD communities, this news is particularly resonant. Research indicates that 17% of hEDS patients and 14.7% of HSD patients meet the criteria for PMOS.
The overlap between these conditions is not merely statistical; it is symptomatic of a larger, systemic failure in medicine. Just as the hEDS community has fought for decades against the label of "just being flexible," the PMOS community has fought against the label of "just having cysts." Both patient populations face:
- Diagnostic Delays: The average diagnostic delay for hEDS is 22 years; PMOS patients face similarly protracted journeys.
- Fragmented Care: Both conditions are multisystemic, yet they are often treated by specialists who only look at one "part" of the patient.
- Stigma: Both conditions have been historically dismissed as "lifestyle" issues or "mild" concerns, despite the significant, life-altering pain and systemic dysfunction they cause.
Emerging studies suggest that hormonal factors, potentially linked to the connective tissue fragility seen in hEDS, may play a role in the high comorbidity rates of these conditions. By legitimizing PMOS as a complex endocrine-metabolic disease, the medical field is finally acknowledging that these patients require integrated, multispecialty care.
Diagnostic Criteria: A Standardized Approach
Despite the name change, the clinical diagnostic criteria—established in the 1990s and refined in 2003—remain the gold standard for identification. Patients are diagnosed if they meet two of the following three criteria (adolescents aged 10–19 must meet the first two):
-
Clinical or Biochemical Hyperandrogenism:
- Biochemical: Bloodwork confirming elevated total or free testosterone, or bioavailable testosterone.
- Clinical: Visible signs such as hirsutism, measured via the Ferriman-Gallwey score, which assesses hair growth across nine body regions.
-
Oligo-Anovulation:
- A spectrum of ovulatory dysfunction, often manifesting as cycles longer than 35 days or fewer than eight menstrual cycles per year (oligo-amenorrhea).
-
Polycystic Ovarian Morphology:
- Ultrasound confirmation of ovaries containing ≥20 follicles, or an ovarian volume ≥10 cm³.
Implications for the Future
The shift to PMOS is a victory for evidence-based medicine. It moves the focus away from the visual presence of cysts and toward the physiological reality of endocrine and metabolic dysfunction.
For Researchers: The renaming opens the door to cross-disciplinary studies. We can now expect to see more research linking the metabolic drivers of PMOS with heart disease, insulin regulation, and even the connective tissue issues seen in the hypermobility community.
For Policy Makers: The formal integration of PMOS into the ICD and international guidelines means that funding bodies can no longer ignore the systemic nature of the condition. It forces a change in how clinical pathways are funded and how insurance covers treatments that fall outside of traditional gynecological care.
For Patients: The name is an identity. For those who felt "imposter syndrome" because their ultrasounds were "normal" despite their suffering, the term "Polyendocrine Metabolic" offers a clear, medically accurate validation of their symptoms. It tells the patient that their insulin resistance, their hair growth, their cycles, and their systemic fatigue are all parts of one, cohesive, and legitimate medical condition.
As we look toward 2028, when the new international guidelines are fully implemented, the medical community has a clear mandate: treat the patient, not just the ovary. By finally calling the condition by its true name, we have moved one step closer to the care, respect, and scientific attention that these millions of patients deserve.
Tayler Goectau is a clinical research coordinator and disability advocate. For more information on this transition and its impact on the hEDS community, visit chronicpainpartners.com.
